Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD) with bullish sentiments.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Forte Biosciences (FBRX)

Guggenheim analyst Yatin Suneja reiterated a Buy rating on Forte Biosciences yesterday and set a price target of $75.00. The company’s shares closed last Thursday at $36.70.

According to TipRanks.com, Suneja is a 5-star analyst with an average return of 35.0% and a 61.0% success rate. Suneja covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Praxis Precision Medicines, and Neumora Therapeutics, Inc. ;'>

Currently, the analyst consensus on Forte Biosciences is a Strong Buy with an average price target of $67.00.

See today’s best-performing stocks on TipRanks >>

Sarepta Therapeutics (SRPT)

Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics today and set a price target of $31.00. The company’s shares closed last Thursday at $20.52.

According to TipRanks.com, Ear is a 4-star analyst with an average return of 10.2% and a 46.5% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Cartesian Therapeutics, and ACADIA Pharmaceuticals. ;'>

Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $23.21, representing a 13.8% upside. In a report issued on July 8, Wolfe Research also upgraded the stock to Buy with a $27.00 price target.

Opus Genetics (IRD)

LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Opus Genetics today and set a price target of $10.00. The company’s shares closed last Thursday at $4.02.

According to TipRanks.com, Brisebois is a 4-star analyst with an average return of 6.6% and a 43.2% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Tarsus Pharmaceuticals, and Aquestive Therapeutics. ;'>

Opus Genetics has an analyst consensus of Strong Buy, with a price target consensus of $11.14, implying a 170.4% upside from current levels. In a report issued on July 6, Chardan Capital also maintained a Buy rating on the stock with a $13.00 price target.

Read More on FBRX:

Disclaimer & DisclosureReport an Issue

• First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright
• Midday Fly By: PepsiCo reports mixed Q2, Levi Strauss posts ‘beat and raise’
• Forte Biosciences trading resumes
• Forte Biosciences trading halted, volatility trading pause
• Forte Biosciences Reports Positive Phase 1b Vitiligo Results